The European Medicines Agency EMA has recommended the granting of marketing authorization for Ixchiq*, the first anti-Chikungunya vaccine to be used in the EU to protect adults aged 18 and over. The regulatory body announced this by communicating the favorable opinion of the Committee for Medicinal Products for Human Use (CHMP). The vaccine is administered as a single dose.
“Climate change may be at the origin of many of the health threats we face today – highlights the EMA – The increase in cases of vector-borne diseases”, which travel on infected mosquitoes “such as Chikungunya is a clear example of the impact of climate change on health and reinforces the need for a One Health approach.
The CHMP’s green light represents an intermediate step in Ixchiq’s journey towards patient access. The opinion will now be sent to the European Commission for the adoption of a decision on the marketing authorization at Community level. Once marketing authorization has been granted, the EMA reminds us, decisions on price and reimbursement will take place at the level of each Member State, taking into account the potential role and use of this medicine in the context of that country’s national healthcare system. specific country.
#Chikungunya #Ema #vaccine #18s
